Navigation Links
Mylan Launches First Generic Version of Vfend® Tablets
Date:2/15/2011

PITTSBURGH, Feb. 15, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Voriconazole Tablets, 50 mg and 200 mg, under a previously announced settlement and license agreement with Pfizer Inc. Mylan was the first company to have filed a substantially complete ANDA containing a Paragraph IV certification for Voriconazole Tablets and was awarded 180 days of marketing exclusivity.  

Voriconazole Tablets are the generic version of Pfizer's Vfend® Tablets, a triazole antifungal agent. This product had U.S. sales of approximately $186 million for the 12 months ending Dec. 31, 2010, according to IMS Health.

Currently, Mylan has 170 ANDAs pending FDA approval representing $97.7 billion in annual sales, according to IMS Health. Forty-five of these pending ANDAs are potential first-to-file opportunities, representing $24.2 billion in annual brand sales, for the 12 months ending June 30, 2010, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Mylan Receives Approval for First-to-File Generic Sular® Extended-Release Tablets
2. Mylans Matrix Obtains License for Promising HIV/AIDS Treatment
3. Mylan Announces Lipitor® Settlement Agreement
4. Mylan Announces Caduet® Settlement Agreement
5. Mylans Matrix Receives Approval for Generic Version of Protonix® Delayed-release Tablets
6. Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for Lamivudine and Zidovudine Tablets, 30 mg/60 mg
7. Mylan Receives Approval for Generic Version of Precose® Tablets
8. Mylan Announces Voluntary De-listing of 1.25% Senior Convertible Notes Due 2012 from Nasdaq
9. Mylans Dey Pharma Partners with Meda to Market EpiPen® Auto-Injector in Europe
10. Mylan Confirms First-to-File Patent Challenge Relating to Orapred ODT®
11. Mylan Receives Approval for Generic Version of Adalat® CC Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2017)... , Jan. 14, 2017  Johnson & Weaver, LLP ... of purchasers of Zimmer Biomet Holdings, Inc. (NYSE: ... through October 31, 2016 (the "Class Period"). Zimmer ... and markets orthopaedic reconstructive products, such as knee and hip ... ...
(Date:1/13/2017)... Eli Lilly and Company (NYSE: ... ) announced today that the U.S. Food and Drug ... new drug application (NDA) for investigational baricitinib, a once-daily ... rheumatoid arthritis (RA). The NDA for baricitinib was submitted ... FDA extended the action date to allow time to ...
(Date:1/13/2017)... New York , January 13, 2017 ... rising prevalence of AIDS will collectively contribute to the demand ... expected to reach a value of US$ 551.0 Mn by ... will remain the most lucrative markets for western blotting, ... lead the market globally. ...
Breaking Medicine Technology:
(Date:1/16/2017)... , ... January 16, 2017 , ... St. Louisans are well-aware of the following facts ... This year’s influenza shot seems to be having no effect on keeping this particularly ... half of the people around are coughing, sneezing, or sniffling , These ...
(Date:1/16/2017)... ... ... San Francisco dentist, Dr. Ben Amini , the founder at CitiDent, ... capable of taking digital impressions of teeth and gums. Conventional bite impressions have lagged ... , in terms of speed, efficiency and patient comfort. Increasingly, digital impressions are being ...
(Date:1/15/2017)... ... January 15, 2017 , ... Whole Health Supply, LLC is announcing the release of an ... new avenues for purchase. , The 2017 edition has wide jaws that will accommodate ... older boomers as well as diabetics. This handle is reinforced for extra strength when pressing ...
(Date:1/15/2017)... ... January 15, 2017 , ... The Gravity Vault Indoor Rock Climbing Gym is ... wraps up on the 14,000+ square foot climbing gym, the owners anticipate to open ... in New Jersey and two in New York. With this being its first location ...
(Date:1/14/2017)... ... , ... "TransFreeze Volume 3 is a self animating masking transition which allows users to reveal ... said Christina Austin - CEO of Pixel Film Studios. , TransFreeze Volume 3 provides ... clip to the next. , To use “Cut-Out First” presets, choose a video ...
Breaking Medicine News(10 mins):